Compare Hyatt Hotels Corporation (H) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Viatris Inc — how do they compare? Hyatt Hotels Corporation trades at $189 (market cap $17.85B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Hyatt Hotels Corporation and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| H | VTRS | |
|---|---|---|
Market Cap | $17.85B | $19.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $17.39 |
52-Week Low | $135.01 | $8.74 |
Enterprise Value | $21.69B | $32.00B |
Dividend Yield | 0.32% | 2.83% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
